Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318424 | 0.91 | PTGS2 (0.44) | MAP4K4PTGS2GABRA5FFAR4ESR1 | |
| SCHEMBL2319376 | 0.90 | PTGS2 (0.46) | MAP4K4PTGS2GABRA5FFAR4ESR1 | |
| SCHEMBL2318362 | 0.88 | GABRA5 (0.52) | PTGS2GABRA5FFAR4MAP2K4 | |
| SCHEMBL2318109 | 0.86 | PTGS2 (0.46) | PTGS2FFAR4ESR1ESR2 | |
| SCHEMBL2319468 | 0.85 | GABRA5 (0.55) | PTGS2GABRA5 | |
| SCHEMBL2321175 | 0.85 | GABRA5 (0.54) | GABRA5 | |
| SCHEMBL2317325 | 0.84 | ESR1 (0.48) | PTGS2FFAR4ESR1ESR2 | |
| SCHEMBL2319828 | 0.84 | GABRA5 (0.57) | PTGS2GABRA5 | |
| SCHEMBL2319935 | 0.83 | PTGS2 (0.44) | PTGS2GABRA5FFAR4ESR1ESR2 | |
| SCHEMBL2324037 | 0.83 | ESR1 (0.47) | MAP4K4PTGS2GABRA5FFAR4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170873-B1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| US-7851469-B2 | Isoxazole-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | claimed |
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | claimed |
| EP-2170873-B1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-7851469-B2 | Isoxazole-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | GABRA5, GABRA1, GABRA4 | MAP4K4 3804/4885PTGS2 2317/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.